To appraise the clinical and cost effectiveness of peginterferon beta-1a within its marketing authorisation for treating relapsing–remitting multiple sclerosis.
 
Status In progress
Process STA 2018
ID number 1521

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Biogen Idec (peginterferon beta-1a)
Others Department of Health and Social Care
  NHS England
  NHS Leeds CCG
  NHS Portsmouth CCG
  Welsh Government
Patient carer groups Brain and Spine Foundation
  The Brain Charity
  Disability Rights UK
  Leonard Cheshire Disability
  MS-UK
  Multiple Sclerosis National Therapy Centres
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Muslim Council of Britain
  Neurological Alliance
  Shift.ms
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  British Association of Neuroscience Nurses
  British Geriatrics Society
  British Neuropathological Society
  British Society of Rehabilitation Medicine
  Chartered Society of Physiotherapy
  Institute of Neurology
  Primary Care Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Occupational Therapists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Multiple Sclerosis Specialist Nurse Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Biogen Idec (dimethyl fumarate, interferon beta-1a, natalizumab)
  Genzyme (alemtuzumab, teriflunomide)
  Merck (interferon beta-1a, cladribine)
  Mylan (glatiramer acetate)
  Novartis (interferon beta-1b, fingolimod)
  Roche (ocrelizumab)
  Teva UK (glatiramer acetate)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Multiple Sclerosis Society Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research Trust
  British Neurological Research Trust
  Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
29 March 2019 In progress, The final scope was issued.
29 March 2019 Invitation to participate
13 February 2019 Draft scope documents

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance